STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals

Kalshi is introducing prediction markets to the biopharma sector, aiming to revolutionize how clinical trials and FDA approvals are approached. By leveraging market predictions, the company hopes to enhance transparency, efficiency, and stakeholder engagement in drug development and regulatory processes. This innovation could democratize information and make it easier for investors and patients to gauge the potential success of clinical trials. It's a significant move that could reshape the biopharma landscape, offering a fresh perspective on risk assessment and decision-making.